AP5346 (ProLindac™), a dach platinum polymer conjugate in Phase II trials against ovarian cancer

Current Bioactive Compounds

Volumn 7, Issue 1, 2011, Pages 21-26

  Nowotnik, David P ^a  

^a Access Pharmaceuticals Inc   (United States)

Author keywords

AP5346; Clinical trials; DACH platinum; HPMA polymer; ProLindac; Recurrent ovarian cancer; Tumor targeting

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; AP 5346; CARBOPLATIN; FLUOROURACIL; GEMCITABINE; HYDROXYPROPYLMETHACRYLAMIDE; OXALIPLATIN; PLATINUM 1,2 DIAMINOCYCLOHEXANE; POLYMER; PRODRUG; PROLINDAC; UNCLASSIFIED DRUG;

ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IN VITRO STUDY; LEUKOPENIA; LYMPHOCYTOPENIA; MONOTHERAPY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PH; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA;

EID: 79953905761     PISSN: 15734072     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340711795163794     Document Type: Article

References (36)

1. Rosenberg, B., Van Camp, L., Krigas, T. Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 1965, 205, 698.
2. Guminski, A.D., Harnett, P.R., DeFazio, A. Scientists and clinicians test their metal-back to the future with platinum compounds. Lancet Oncol., 2002, 3, 312-318.
3. Chen, D., Milacic, V., Frezza, M., Dou, Q.P. Metal complexes, their cellular targets and potential for cancer therapy. Curr. Pharm. Des., 2009, 15, 777-791.
4. Galanski, M., Keppler, B.K. Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anti-Cancer Agents Med. Chem., 2007, 7, 55-73.
5. Shah, N., Dizon, D.S. New-generation platinum agents for solid tumors. Future Oncol., 2009, 5(1), 33-42.
6. Choy, H., Park, C., Yao, M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin. Cancer Res., 2008, 14, 1633-1638.
7. Kelland, L. Broadening the clinical use of platinum drug-based chemotherapy with new analogues: Satraplatin and picoplatin. Expert Opin. Investig. Drugs, 2007, 16(7), 1009-1021.
8. Lokich, J. Anderson, N. Carboplatin versus cisplatin in solid tumors: an analysis of the literature. Ann. Oncol., 1998, 9, 13-21.
9. Simpson, D., Dunn, C., Curran, M., Goa, K.L. Oxaliplatin-a review of its use in combination therapy for advanced metastatic colorectal cancer. Drugs, 2003, 63, 2127-2156.
10. Pabla, N. Dong, Z. Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int., 2008, 73, 994-1007.
11. Duffull, S.B., Robinson, B.A. Clinical pharmacokinetics and dose optimisation of carboplatin. Clin. Pharmacokinet., 1997, 33, 161-183.
12. Kannarkat, G., Lasher, E.E., Schiff, D. Neurologic complications of chemotherapy agents. Curr. Opin. Neurol., 2007, 20, 719-725.
13. Pasetto, L.M., D'Andrea, M.R., Rossi, E., Monfardini, S. Oxaliplatin-related neurotoxicity: how and why? Crit. Rev. Oncol. Hematol., 2006, 59, 159-168.
14. Giaccone, G. Clinical perspectives on platinum resistance. Drugs, 2000, 59, 9-17.
15. Maeda, H., Bharate, G.Y., Daruwalla, J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur. J. Pharm. Biopharm., 2009, 71, 409-419.
16. Heath, J.R., Davis, M.E. Nanotechnology and cancer. Ann. Rev. Med., 2008, 59, 251-265.
17. Moses, M.A., Brem, H., Langer, R. Advancing the field of drug delivery: taking aim at cancer. Cancer Cell, 2003, 4, 337-341.
18. Lammers, T., Hannink, W.E., Storm, G. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer, 2008, 99, 392-397.
19. Haxton, K.J. Burt, H.M. Polymeric drug delivery of platinum-based anticancer agents. J. Pharm. Sci., 2009, 98, 2299-2316.
20. Gianasi, E., Wasil, M., Evagorou, E.G., Keddle, A., Wilson, G., Duncan, R. HPMA copolymer platinates as novel antitumour agents: in vitro properties, pharmacokinetics and antitumour activity in vivo. Eur. J. Cancer, 1999, 35, 994-1002.
21. Gianasi, E., Buckley, R.G., Latigo, J., Wasil, M., Duncan, R. HPMA copolymers platinates containing dicarboxylato ligands. Preparation, characterisation and in vitro and in vivo evaluation. J. Drug Target, 2002, 10, 549-556.
22. Lin, X., Zhang, Q., Rice, J.R., Stewart, D.R., Nowotnik, D.P., Howell, S.B. Improved targeting of platinum chemotherapeutics. The antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur. J. Cancer, 2004, 40, 291-297.
23. Bouma, M., Nuijen, B., Harms, R., Rice, J.R., Nowotnik, D.P., Stewart, D.R., Jansen, B.A., van Zutphen, S., Reedijk, J., van Steenbergen, M.J., Talsma, H., Bult, A., Beijnen, J.H. Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280. Drug Dev. Ind. Pharm., 2003, 29, 981-995.
24. Bouma, M., Nuijen, B., Stewart, D.R., Shannon, K.F., St John, J.V., Rice, J.R., Harms, R., Jansen, B.A., van Zutphen, S., Reedijk, J., Bult, A., Beijnen, J.H. Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280. PDA J. Pharm. Sci. Technol., 2003, 57, 198-207.
25. Bouma, M., Nuijen, B., Stewart, D.R., Rice, J.R., Jansen, B.A., Reedijk, J., Bult, A., Beijnen, J.H. Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential. Anticancer Drugs, 2002, 13, 915-924.
26. Tibben, M.M., Rademaker-Lakhai, J.M., Rice, J.R., Stewart, D.R., Schellens, J.H., Beijnen, J.H. Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry. Anal. Bioanal. Chem., 2002, 373, 233-236.
27. Rademaker-Lakhai, J.M., Terret, C., Howell, S.B., Baud, C.M., De Boer, R.F., Pluim, D., Beijnen, J.H., Schellens, J.H., Droz, J.P. A phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin. Cancer Res., 2004, 10, 3386-3395.
28. Rice, J.R., Gerberich, J.L., Nowotnik, D.P., Howell, S.B. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin. Cancer Res., 2006, 12, 2248-2254.
29. Nowotnik, D.P. Cvitkovic, E. ProLindac (AP5346): a reviews of the development of an HPMADACH platinum polymer therapeutic. Adv. Drug Deliv. Rev., 2009, 61, 1214-1219.
30. nd, K.B., Jacob, J.E., Waller, L.K., Silva, G.O., Stewart, D.R., Nowotnik, D.P. Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent. Bioconjug. Chem., 2006, 17, 1270-1279.
31. nd, K.B., Stewart, D.R., Rice, J.R., Beijnen, J.H. Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346. Pharmazie, 2006, 61, 835-844.
32. Jerremalm, E., Wallin, I., Yachnin, J., Ehrsson, H. Oxaliplatin degradation in the presence of important biological sulphur-containing compounds and plasma ultrafiltrate. Eur. J. Pharm. Sci., 2006, 28, 278-283.
33. th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy, Verona, Italy, November 2007.
34. thEORTC-NCI-AACR Conference in Geneva, Switzerland, October 2008.
35. Serova, M. Antiproliferative effects of ProLindac, a novel DACHplatinum linked polymer compound, as a single agent and in combination with other anticancer drugs in a panel of human cancer cell lines, Presented at the 10th International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy, Verona, Italy, November 2007.
36. Campone, M., Rademaker-Lakhai, J.M., Bennouna, J., Howell, S.B., Nowotnik, D.P., Beijnen, J.H., Schellens, J.H. Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother. Pharmacol., 2007, 60, 523-533.